FGF21 and metabolic dysfunction-associated steatohepatitis: Similar to patients with MASH and obese individuals who exhibit increased circulating FGF21 levels, an increase in plasma FGF21 concentrations has been reported in DIO mice, which also exhibit FGF21 resistance due to desensitization of FGFR1/KLB signaling [38].